Technologic Considerations of Creation Dosage Form of Original Substance 3,7-diazabicyclo[3.3.1]nonane

Introduction. An innovative pharmaceutical substance based on the 3,7-diazabicyclo[3.3.1]nonane derivative provides long-term activation of AMPA receptors and the production of neurotrophic factors, which makes it possible to use it for the treatment of cognitive impairments and rehabilitation of patients who have undergone acute brain hypoxia. Given that this substance is able to be absorbed through the walls of the gastrointestinal tract and pass through the blood-brain barrier, there are no restrictions on the development of an oral dosage form. In addition, the oral dosage form has significant advantages when used in geriatric and pediatric practice.

Aim. The aim of the work was to carry out a comparative study of the possibility of using gelatin and hypromellose capsules for the development of the composition and technology for obtaining a dosage form containing a pharmaceutical substance based on a 3,7-diazabicyclo[3.3.1]nonane derivative.

Materials and methods. The study of the «Dissolution» test of gelatinous and hypromellose capsules was carried out on an ERWEKA DT 720 «Paddle stirrer» apparatus at a stirrer rotation speed of 50 rpm in three media: pH 1.2, pH 4.5 and pH 6.8. The content of the substance in each sample was determined by high performance liquid chromatography with UV detection.

Results and discussion. The results of the development and testing of capsules containing an original pharmaceutical substance of nootropic action based on a derivative of 3,7-diazabicyclo[3.3.1]nonane, which has low pharmaceutical and technological characteristics and is practically insoluble in water, are presented. The D/S value was ≥250.00 ml in each physiological pH range. The results of determining the dissolution of the developed dosage form in three media at pH values of 1.2, 4.5 and 6.8 showed a positive effect of the technology used on the solubility of the substance.

Conclusion. A significant increase in the solubility of the practically insoluble substance of the 3,7-diazabicyclo[3.3.1]nonane derivative in the developed dosage form was shown, which is the result of the use of a well-founded complex of excipients and the technology of moisture-activated granulation. According to the results obtained, (77.60 ± 2.50) % of the substance passes into the dissolution medium with a pH of 4.5 in 45 minutes. The research results are used to develop a technological scheme for obtaining a finished dosage form, its indicators and quality standards.

1. Zapolskiy M. E., Lavrov M. I., Palyulin V. A., Zefirov N. S. RF Patent No. RU 2480470 C2. Tricyclic derivatives of N, N-substituted 3,7-diazabicyclo[3.3.1]nonanes with pharmacological activity and drugs based on them. 2013. (In Russ.).

2. Pyatigorskaya N. V., Brkich G. E., Lavrov M. I., Palyulin V. A., Aladysheva Z. I. New AMPA receptor positive modulators for rehabilitation of patients after cerebral accidents. Journal of Pharmaceutical Sciences and Research. 2018;10(5):1103–1106.

3. Brkich G. E., Pyatigorskaya N. V., Demina N. B., Zyryanov O. A., Krasnyuk I. I. Scientific and Methodical approach to developing the formulation of an Innovative Medicinal Product based on a derivative of 3,7-diazabicyclo[3.3.1]nonane (hydrindane). Research J. Pharm. and Tech. 2019;12(12):5752–5756.

4. Demina N. B., Demina M. S. Development of technology for the production of capsule forms of drugs. Chapter in the monograph Pharmaceutical Development. Concept and practical recommendations. Moscow. Publisher Pero. 2015. P. 196–236. (In Russ.).

5. Demina N. B. Biopharmaceutical classification system as a tool for the development of drug formulations and their designs. Razrabotka i registratsiya lekarstvennykh sredstv = Drug development & Registration. 2017;(2):56–60. (In Russ.).

6. Technical Reference File Hard Gelatin Capsules. 3rd edition. Capsugel. 2010. 55 p.

7. State Pharmacopoeia of the Russian Federation. XIV edition. 2018. (In Russ.).